Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy

Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy

Aim: 177Lu-Dotatate (Lu-177), a form of peptide receptor radionuclide therapy (PRRT), was approved by Food and Drug Administration (FDA) for the treatment of somatostatin-receptor-positive neuroendocrine tumors (NETs) in 2018. Clinical trials prior to the FDA approval of Lu-177 showed favorable outc...

Full description

Saved in:
Bibliographic Details
Main Authors: Stijn Hentzen (Author), Kathan Mehta (Author), Raed Moh'd Taiseer Al-Rajabi (Author), Anwaar Saeed (Author), Joaquina Celebre Baranda (Author), Stephen K. Williamson (Author), Weijing Sun (Author), Anup Kasi (Author)
Format: Book
Published: Open Exploration Publishing Inc., 2023-06-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items